Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022)
Xenon Pharmaceuticals (XENE) posted quarterly Non Operating Investment Income of -$1.3 million for Q2 2022, down 7476.47% year-over-year from $17460.9 in Q2 2021, and up 61.69% quarter-over-quarter from -$3.4 million in Q1 2022.
Powered by 
Analysis
Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2021 - 2022) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Non Operating Investment Income for 2 consecutive years, with -$1.3 million the latest figure, recorded in Q2 2022.
- In Q2 2022, Non Operating Investment Income fell 7476.47% year-over-year to -$1.3 million; the TTM figure through Jun 2022 stood at -$4.7 million (changed N/A YoY), while the FY2021 annual figure was -$719000.0, down 18075.0% from the prior year.
- Non Operating Investment Income rose to -$1.3 million in Q2 2022 per XENE's latest filing, from -$3.4 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at -$17000.0 in Q2 2021 and bottomed at -$3.4 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Xenon Pharmaceuticals | 5.95 Bn | 5.95 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | -1.29 Mn |
| Mar 31, 2022 | -3.36 Mn |
| Jun 30, 2021 | -17,000.00 |
| Mar 31, 2021 | -74,000.00 |